Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Rated “Hold” by Wall Street Brokerages

Heron Therapeutics, Inc. (NASDAQ:HRTX) has been assigned a consensus rating of “Hold” from the five analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $2.00.

A number of research analysts have weighed in on the stock. Zacks Research upgraded shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Thursday, October 15th. Wall Street Zen upgraded Heron Therapeutics to a “sell” rating in a research report on Saturday, August 8th. Finally, HC Wainwright lowered Heron Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 11th.

Heron Therapeutics Stock Performance

HRTX opened at $0.30 on Tuesday. The firm has a fifty day moving average price of $0.33 and a 200 day moving average price of $0.72. Heron Therapeutics has a 1 year low of $0.26 and a 1 year high of $1.57. The stock has a market cap of $57.09 million, a P/E ratio of -1.58 and a beta of 1.62. The company has a debt-to-equity ratio of 24.35, a current ratio of 2.49 and a quick ratio of 1.51.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.03) EPS for the quarter. Heron Therapeutics had a negative net margin of 22.52% and a negative return on equity of 293.02%. The firm had revenue of $37.67 million for the quarter, compared to analyst estimates of $42.19 million. Equities research analysts anticipate that Heron Therapeutics will post -0.14 earnings per share for the current year.

Institutional Trading of Heron Therapeutics

Several institutional investors have recently bought and sold shares of the business. R Squared Ltd purchased a new stake in shares of Heron Therapeutics in the first quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Heron Therapeutics by 335.2% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 35,106 shares of the biotechnology company’s stock valued at $46,000 after buying an additional 27,040 shares in the last quarter. HORAN Wealth LLC purchased a new position in shares of Heron Therapeutics during the 1st quarter valued at approximately $33,000. Deutsche Bank AG acquired a new stake in Heron Therapeutics in the 2nd quarter valued at $41,000. Finally, Ieq Capital LLC acquired a new stake in Heron Therapeutics in the 2nd quarter valued at $41,000. 80.01% of the stock is owned by institutional investors and hedge funds.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and marketing medicines for acute care and oncology supportive care. Its products are designed to address unmet needs such as postoperative pain and chemotherapy-induced nausea and vomiting.

The company’s portfolio includes ZYNRELEF, an extended-release solution combining bupivacaine and meloxicam for the management of postoperative pain in adults. Heron also markets CINVANTI, an injectable formulation of aprepitant used as part of a combination regimen to help prevent acute and delayed nausea and vomiting associated with highly or moderately emetogenic cancer chemotherapy.

Heron’s commercial activities are primarily focused on the United States, where it works with healthcare providers and institutions to support the use of its products in surgical and oncology settings.